# Phase I/Ib Trial of TIraGolumab, AtEzolizumab, and RadScopal Radiation in Patients With Advanced Solid Malignancies (TIGER)

> **NCT06760481** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 7 (actual)

## Conditions studied

- Advanced Solid Malignancies

## Interventions

- **DRUG:** Tiragolumab
- **DRUG:** Atezolizumab
- **RADIATION:** Radiation Therapy

## Key facts

- **NCT ID:** NCT06760481
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-04-13
- **Primary completion:** 2028-09-15
- **Final completion:** 2030-09-15
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2026-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06760481

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06760481, "Phase I/Ib Trial of TIraGolumab, AtEzolizumab, and RadScopal Radiation in Patients With Advanced Solid Malignancies (TIGER)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06760481. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*